Successful treatment of human eumycetomas caused by Aspergillus species with voriconazole
DOI:
https://doi.org/10.66344/jpad.v31i1.1595Keywords:
Eumycetoma, voriconazole, Aspergillus niger, Aspergillus flavus, Aspergillus fumigatus.Abstract
Background Mycetoma is a chronic, granulomatous infection of skin, soft tissues and bones which developed after traumatic inoculation of pathogenic spores deep in to the tissues. Classical triad consists of swollen tissues, draining sinuses and coloured grains.
Objective This study aimed to document clinical impact, side effects and safety profile of voriconazole in Aspergillus eumycetomas.
Methods Retrospective study of clinical, histopathological and culture proven cases of Aspergillus eumycetomas treated with voriconazole between October 2017 to March 2020. Voriconazole 400 mg/day was given for six to 15 months.
Results Six patients were selected for the study. Male to female ratio was 1:1. Mean age of cases was 45.33 years; five belonged to rural areas; most common occupation was farmer; feet were involved in five while knee was involved in one case only. Mean delay in diagnosis was 9.33 years. KOH mount showed filamentous, septate, acute-angled, dichotomously branched hyphae in all cases. Histopathology was diagnostic in four cases. Culture was positive in all cases and reported Aspergillus flavus in three, Aspergillus niger in two and Aspergillus fumigatus in one case. Bone involvement was none to minimal. Cultures became negative after three months of therapy while clinical improvement required at least six months of drug treatment. Surgical intervention was required in four cases. None of the case ended up for amputation. Five cases achieved complete clinical and microbiological cure.
Limitations Single center study, small sample, lack of molecular identification facilities.
References
1. Verma P, Jha A. Mycetoma: reviewing a neglected disease. Clin Exp Dermatol. 2019;44:123-9.
2. Welsh O, Salinas-Carmona MC, La Garza JAC, Rodriguez-Escamilla IM, Sanchez-Meza E. Current treatment of mycetoma. Curr Treat Options Infect Dis. 2018;10:389–96.
3. Reis CMS, Reis-Filho EGM. Mycetomas: an epidemiological, etiological, clinical, laboratory and therapeutic review. An Bras Dermatol. 2018;93:8-18.
4. Fahal AH, Sabaa AHA. Mycetoma in children in Sudan. Trans R Soc Trop Med Hyg. 2010;104:117–21.
5. Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES, Goodfellow M, Fahal AH. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis. 2016;16:100-12.
6. Fahal A, Mahgoub ES, Hassan AME, Abdel-Rahman ME. Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan. PLoS Negl Trop Dis. 2015;9(3):e0003679.
7. Mallick YA. An unusual case of mixed mycetoma by actinomycete and aspergillus species. Pak J Med Dentistry. 2020;9:113-6.
8. Bennett JW. An overview of the genus Aspergillus. In: Bennett JW, editor. Aspergillus: molecular biology and genomics. Poole: Caister Academic Press; 2010. p. 1-17.
9. Ahmed SA, Abbas MA, Jouvion G, Al-Hatim AM, de Hoog GS, Kolecka A, et al. Seventeen years of subcutaneous infection by Aspergillus flavus; eumycetoma confirmed by immunohistochemistry. Mycoses. 2015;58:728-34.
10. Mallick YA, Yaqoob N. Aspergillus niger causing eumycetoma in an immunocompetent host: report of a case and review of the literature. J Dow Univ Health Sci. 2020;14:42-4.
11. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1-e60.
12. Aspergillus & Aspergillosis website [Internet]. What is aspergillus? c2006 [updated 2018; cited 2020 July 15]. Available at: https://www.aspergillus.org.uk
13. Zaman SU, Sarma DP. Maxillary sinus mycetoma due to Aspergillus niger. Internet J Otorhinolaryngol. 2006;6(1):1-4.
14. Drugbank [Internet]. Voriconazole; c2005. [updated 2020 July 11; cited 2020 July 15]. Available at: https://www.drugbank.ca/drugs/DB00582
15. Hopps S, Roach A, Yuen C, Borders E. Treatment for a eumycetoma infection caused by Aspergillus in an immunocompromised host: a case report. Transpl Infect Dis. 2015:17:94–7.
16. Porte L, Khatibi S, Hajj LE, Cassaing S, Berry A, Massip P, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg. 2006;100:891–4.
17. Padhi S, Uppin SG, Uppin MS, Umabala P, Challa S, Laxmi V, et al. Mycetoma in South India: retrospective analysis of 13 cases and description of two cases caused by unusual pathogens: Neoscytalidium dimidiatum and Aspergillus flavus. Int J Dermatol. 2010;49:1289–96.
18. Tendolkar U, Sheth B, Baveja S, Mehta N, Samaddar A, Banshelkikar S, et al. Unusual presentation of Madurella mycetomatis mycetoma in a paediatric patient in India. MOJ Clin Med Case Rep. 2016;4(5):109-11.
19. Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF. Invasive aspergillosis by Aspergillus flavus: epidemiology, diagnosis, antifungal resistance, and management. J Fungi. 2019;5:55.
20. Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 2015;21-22:30-40.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Yousuf Abd Mallick, Nausheen Yaqoob, Kanwal Aftab, Fahad Abd Mallick, Qurat ul Ain Zahid
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
